XJPX
6034
Market cap21mUSD
Jul 10, Last price
635.00JPY
1D
0.63%
1Q
2.42%
Jan 2017
-64.00%
IPO
-55.59%
Name
MRT Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MRT Inc. operates a medical information platform. It provides Gaikin, a recruitment service specializing in part-time physicians; career, a job change support service for doctors; re:ray, a one stop outsourcing service; Door., an app to connect network of doctors; Door.into, an app platform that connects doctors and medical institutions with individuals; Pocket Doctor, a telemedicine app; groupware for medical departments; and FASTCALL a safety confirmation service for medical institutions consolidating the functions for hospital crisis management systems. The company also offers stem cell culture supernatant for medical institutions; pharmacist, clinical engineering technician, radiologic technologists, dialysis nurses, new practice openings and succession cases, clinical laboratory technician, and nurse recruitment services; job posting service for full-time and part-time industrial physicians; occupational health services; employment placement services; life support services; and full-time, part-time, and temporary positions for healthcare and welfare professionals. In addition, it engages in book publishing on illness and treatment; medical worker job placement business; business start-up; business succession support business; PR services, comprehensive membership compensation system, tax accountant referral services, and human umbilical cord-derived culture supernatant. Further, it offers anew, a service aimed at payroll calculation for doctors part-time jobs and payroll transfer agency services; Medikiki, an information distribution platform connecting manufacturers and wholesalers; and Kids Line that provides babysitting services. MRT Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||